A small number of patients with ovarian cancer respond to AstraZeneca's lung cancer drug Iressa, according to research published by scientists at the Fox Chase Cancer Center and Roswell Park Cancer Institute.

The findings, presented last week at the American Association for Cancer Research in Anaheim, Calif., could be significant because previously the drug had only appeared to be effective in a subset of patients with non-small cell lung cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.